Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESH AL 2020 | Targeted therapy for Ph-like ALL

Sarah Tasian • 26 Jun 2020
ESH AL 2020
Acute Lymphoblastic Leukemia Leukemia Dasatinib Imatinib Ruxolitinib

Sarah Tasian, MD, Children’s Hospital of Philadelphia, Philadelphia, PA, reviews a variety of off-label therapeutic strategies for patients with Philadelphia chromosome-like (Ph-like) acute lymphoblastic leukemia (ALL), including the application of tyrosine kinase (TK) inhibitors-based strategies in combination with chemotherapy and how specific genetic mutations within Ph-like ALL may be targeted by specific TK inhibitors.
This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Sarah Tasian

The management of Ph-like ALL: moving towards an individualized precision medicine approach
2:00
The management of Ph-like ALL: moving towards an individualized precision medicine approach
Sarah Tasian • 3 Sep 2025
Diagnostic advances that could further individualize care in ALL
0:40
Diagnostic advances that could further individualize care in ALL
Sarah Tasian • 3 Sep 2025
How advances in molecular sequencing technologies have shaped ALL therapy
1:05
How advances in molecular sequencing technologies have shaped ALL therapy
Sarah Tasian • 3 Sep 2025
Precision medicine in pediatric ALL
1:09
Precision medicine in pediatric ALL
Sarah Tasian • 4 Jun 2023

Related Videos

Unmet needs in CLL genomics: heterogeneity and clinical impact
1:11
Unmet needs in CLL genomics: heterogeneity and clinical impact
Elias Campo • 16 Oct 2026
Insights into key topics most likely to impact day-to-day CLL management
1:40
Insights into key topics most likely to impact day-to-day CLL management
Alessandra Ferrajoli • 16 Oct 2026
Translating current CLL evidence into national guidelines: which gaps remain?
3:33
Translating current CLL evidence into national guidelines: which gaps remain?
Mary Ann Anderson • 16 Oct 2026
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
2:40
Frontline management of Richter’s transformation: current approaches and remaining uncertainties
Philip Thompson • 22 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals